相关实验视频

Updated: May 31, 2025

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

在初级穿皮冠状动脉干预患者中比较蒂卡格勒勒和克洛皮多格勒:单中心回顾性研究

Yufeng Yan¹, Haimei Xu, Yingying Zhao

¹Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China.

Coronary artery disease

|January 22, 2025

概括

在东亚ST段升高心肌梗塞 (STEMI) 患者接受初级皮肤穿冠状动脉干预 (PCI) 时,格显著降低了全因死亡率. 与克洛皮多格雷尔相比,这种P2Y12抑制剂没有增加主要出血事件.

科学领域:

心脏病学心脏病学
药理学药理学是指药理学的学科.
临床研究临床研究

背景情况:

在东亚STEMI患者中,与克洛皮多格勒相比,提卡格勒罗的比较有效性和安全性存在不确定性.
现实世界的数据对于评估P2Y12抑制剂在这个特定人群中的使用至关重要.

研究的目的:

为了比较Ticagrelor和Clopidogrel在接受初级PCI的STEMI患者的临床结果,包括疗效和安全性.
为了确定提卡格勒罗是否可以在没有增加出血风险的情况下提供更好的结果.

主要方法:

从2011年7月到2019年4月,对1124名STEMI患者进行了回顾性分析.
倾向性得分匹配,以平衡基线特征在蒂卡格勒罗和克洛皮多格雷尔组之间.
主要终点:全因死亡 (有效性) 和出血学术研究联盟 3-5型出血 (安全性).

主要成果:

在匹配后,每个组中有420名患者.
提卡格勒组显示所有原因死亡率显著降低 (8.3%与17.1%相比;HR 0.481;P < 0.001).
提卡格勒与心肌梗塞,心血管死亡和支架血栓形成的减少有关,主要出血没有显著差异.

结论:

与克洛皮多格雷尔相比,提卡格雷罗在接受初级PCI的STEMI患者中显著降低了全因死亡.
提卡格勒洛不增加重大出血的发生率,这表明它是一个安全有效的替代品.
在这种患者群体中,提卡格勒可能是克洛皮多格雷尔的可行的替代品.

更多相关视频

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...